Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Septerna, Inc.NASDAQ: SEPN
Total Current Assets · Q3 FY2026 · quarter ended Sep 2026
Total current assets rises 3.2% from a year ago
Total current assets stood at $507.35M at the end of Q3 FY2026, up 3.2% from a year earlier and up 28.1% from the prior quarter. Over 3 fiscal years it compounded at +134.4% a year.
Context
- Total current assets amounted to 81.9% of total assets at the end of Q3 FY2026, up 0.9 pp from a year earlier.
- Total current assets increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +3.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 410.96M USD
- Year-over-year change
- +15.2%
- 3-year CAGR
- +134.4%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 410.96M | +15.2% |
| FY2024 | 2024-12-31 | 356.82M | +216.7% |
| FY2023 | 2023-12-31 | 112.68M | +253.3% |
| FY2022 | 2022-12-31 | 31.89M | — |
Total Current Assets vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's Sep 2026 total current assets of $507.35M is the 3rd highest of the 7 companies compared; the peer median is $436.27M.
- Its year-over-year change of +3.2% is the lowest of 6, against a peer median of +26.7%.
- Total current assets amounts to 81.9% of total assets for SEPN, versus a peer median of 97.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $1.37B | +71.7% | +156.5% | 96.3% | |
KLRAKailera Therapeutics, Inc. | Jun 2026 | $929.17M | — | — | 76.7% |
SEPNSepterna, Inc. | Sep 2026 | $507.35M | +3.2% | +134.4% | 81.9% |
MBXMBX Biosciences, Inc. Common Stock | Sep 2026 | $492.76M | +24.0% | +105.1% | 98.4% |
| Mar 2026 | $379.78M | +26.7% | +48.8% | 90.5% | |
| Mar 2026 | $98.81M | +209.6% | +49.1% | 100.0% | |
| Mar 2026 | $46.32M | +3.7% | -21.0% | 99.9% | |
| Peer median (excluding SEPN) | $436.27M | +26.7% | +49.1% | 97.3% | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.